

Contents

Chapter 1 An Overview of Bile-Acid Synthesis, Chemistry and Function

Dennis Stamp and Gareth Jenkins

1.1	The Bile Acids	1
1.2	Conjugated Bile-Acid Biosynthesis	4
1.3	Bile-Acid Regulation	4
1.3.1	Bile-Acid Receptors (FXR)	4
1.3.2	Cholesterol Receptors (LXR) (NR1H3) and (NR1H2)	5
1.4	Chemistry of Bile Acids and Their Effects on Digestion	6
1.5	Micelles	7
1.6	Biochemical Properties of Bile Acids and Their Effects on the GI Tract	8
1.6.1	Free Bile Acids	9
1.6.2	Glycine-Conjugated BAs	9
1.6.3	Taurine Conjugated dBAs	9
1.7	The Effect of pH on Bile-Acid Solubility	9
1.8	Potential Therapies for the Deleterious Effects of Bile Acids	10
1.9	Summary	11
	References	11

Chapter 2 Bile-Acid Physiology and Measurement

Peter E. Ross

2.1	Bile-Acid Physiology: The Enterohepatic Circulation	14
2.2	Transport in Blood	15

Issues in Toxicology

Bile Acids: Toxicology and Bioactivity

Edited by Gareth Jenkins and Laura J. Hardie

© Royal Society of Chemistry, 2008

2.3	The Hepatocyte	15
2.4	Sodium Taurocholate Co-transporting Protein (NTCP)	16
2.5	Organic-Anion-Transporting Peptide (OATP)	17
2.6	Specificity of OATP and NTCP Transporters	17
2.7	Regulation of Expression	19
2.8	Transport across the Hepatocyte	20
2.9	Bile-Acid Export from the Hepatocyte	21
	2.9.1 Bile-Salt Export Pump (BSEP)	21
	2.9.2 Regulation of BSEP	22
	2.9.3 Other Transporters that Export Bile Acid from the Hepatocyte	25
2.10	Bile Secretion	25
2.11	Water Secretion	27
2.12	Cholangiocytes	27
2.13	Cholangiocyte Secretion	28
2.14	Gallbladder	29
2.15	Small Bowel	30
2.16	Intestinal Fat Absorption	30
2.17	Bile-Acid Absorption	30
	2.17.1 Apical Sodium-Dependent Bile-Acid Transporter (ASBT)	31
	2.17.2 Regulation	32
	2.17.3 Post-Translational Modification	33
2.18	Transport across the Enterocyte	33
2.19	Export into Portal Blood	34
2.20	Colon	35
	2.20.1 Deconjugation	35
	2.20.2 Oxidation of Hydroxyl Groups	35
	2.20.3 Dehydroxylation	35
2.21	Measurement of Bile Acids	36
	2.21.1 Extraction	36
	2.21.2 Hydroxysteroid Dehydrogenases	37
	2.21.3 Chromatographic Assays	37
	2.21.3.1 Gas-Liquid Chromatography (glc)	37
	2.21.3.2 High-Performance Liquid Chromatography (hplc)	38
	2.21.4 Radioimmunoassay	38
	Abbreviations	38
	References	39

Chapter 3 Bile-Acid Induction of Apoptosis in Relation to Gastrointestinal Cancer

*Katerina Dvorak, Harris Bernstein, Claire M. Payne,
Carol Bernstein and Harinder Garewal*

3.1	Introduction	48
-----	--------------	----

3.2	Bile Acids Induce Oxidative/Nitrosative Stress in Cells of the GI Tract	51
3.3	Bile Acids Induce DNA Damage in Cells of the GI Tract	54
3.4	Bile Acids Activate NF- κ B as a Stress Response and Survival Pathway Throughout the GI Tract	54
3.5	Bile Acids Increase Mutant Cells in the GI Tract	55
3.6	Repeated Exposure to High Concentrations of Bile Acids Probably Selects for Apoptosis Resistance in Cells of the GI Tract	56
3.7	Apoptosis Resistance and Increased Mutation	58
3.8	Modes of Cell Death: Apoptosis, Autophagy and Necrosis	59
3.9	Overview	60
	Acknowledgments	61
	References	61

Chapter 4 The Genotoxicity of Bile Acids

Laura J. Hardie

4.1	Introduction	72
4.2	Definitions	72
4.3	Bile Acids as Carcinogens	73
4.4	DNA Adducts	74
4.5	Bile Acids cause DNA Damage	74
4.6	The Role of Reactive Oxygen and Nitrogen Species	76
4.7	Mutagenic Effects of Bile Acids	77
4.8	Bile Acids and Chromosomal Damage	79
4.9	Chemoprevention Strategies	80
4.10	Summary and Concluding Remarks	80
	References	81

Chapter 5 Bile Acids and Colorectal Cancer

Mark A. Hull

5.1	Introduction	84
5.2	Multi-stage Colorectal Carcinogenesis	84
5.3	Evidence that Bile Acids Play a Role in Colorectal Carcinogenesis	86
	5.3.1 Activity of Bile Acids in Rodent Models of CRC	86
	5.3.2 Human Observational Data	86
5.4	Mechanisms of the Carcinogenic Activity of Secondary Bile Acids	89
5.5	Colorectal Cancer Chemoprevention Strategies Targeting Bile Acids	90

5.5.1	Ursodeoxycholic Acid	90
5.5.2	Other Agents Targeting Mucosal Bile Acid Exposure	92
5.5.3	Therapeutic Anti-cancer Use of Bile Acid Conjugates	93
5.6	Summary	93
	Acknowledgement	93
	References	94

Chapter 6 Bile Acids and Oesophageal Adenocarcinoma (OA)

Gareth Jenkins and James Cronin

6.1	Oesophageal Adenocarcinoma	100
6.2	Oesophageal Bile Acid Exposure	101
6.3	Bile Acids and Diet	103
6.4	Duodeno-Gastro-Oesophageal Reflux (DGOR); Animal Models	103
6.5	Duodeno-Gastro-Oesophageal Reflux (DGOR); Clinical Data	105
6.6	Measurement of Bile in the Oesophagus	109
6.7	Mechanisms behind the Carcinogenicity of Bile Acids	110
6.8	The Interplay between Acid and Bile in GORD	112
6.9	Deconjugation of Bile Acids in Nonacidic Stomach	112
6.10	Effect of Acidity on Bile Acid Solubility	113
6.11	Acid-Suppression Therapy and Risks of OA	114
6.12	Bile Acid Therapy	115
6.13	Conclusions	115
	Acknowledgements	116
	References	116

Chapter 7 Bile Acids and Obesity

Lucinda Summers and Laura J. Hardie

7.1	Obesity	122
7.1.1	Epidemiology	123
7.1.2	Morbidity and Mortality	124
7.2	Adipose Tissue	124
7.2.1	Regulation of Fatty Acid and Glucose Metabolism in Adipocytes	125
7.2.2	Adipose Tissue as an Endocrine Organ	126
7.3	Common Complications of Obesity	127
7.3.1	Insulin Resistance	127
7.3.2	Impaired Glucose Tolerance	129
7.3.3	Dyslipidemia	129

<i>Contents</i>	xi
7.4 Effect of Bile Acids on Obesity	130
7.4.1 Bile Acids, the Farnesoid X Receptor (FXR) and Fat Metabolism	132
7.5 Bile-Acid Sequestrants	133
7.5.1 Chemical Composition of BAS	134
7.5.2 Effect of Bile-Acid Sequestrants on Type-2 Diabetes and Obesity	134
7.6 Summary	137
References	137
Chapter 8 The Role of Bile Acids in Cholesterol-Rich Gallstone Formation	
<i>Linzi A. Thomas</i>	
8.1 Introduction	141
8.2 The Triple Defect of Cholesterol GBS Formation	142
8.3 Vesicles versus Micelles	143
8.4 Nucleation of Cholesterol Crystals	143
8.5 Promoters and Inhibitors of Nucleation	144
8.6 Stasis	144
8.7 Indirect Evidence that Gallbladder Motor Dysfunction/Stasis is Important in the Pathogenesis of GBS	145
8.8 The Octreotide Story	145
8.9 Biliary Phospholipid Fatty-Acid Composition	148
8.10 Biliary Bile-Acid Composition	149
8.11 The Adverse Effects of Increased Proportions of DCA in Bile on Cholesterol Gallstone Formation	149
8.12 Mechanism for the Increase in the % Biliary DCA Conjugates in Bile during Octreotide Treatment	151
8.13 The Relationship between Colonic Transit and DCA Metabolism	151
8.14 The Role of Prolonged Intestinal Transit in the Pathogenesis of Conventional Cholesterol Gallstones	151
8.15 The Inter-Relationship between LBTT, Colonic Anaerobic Bacteriology, Bile-Acid-Metabolising Enzymes, Intraluminal pH and DCA Metabolism	152
8.16 Summary	156
References	156
Subject Index	159

